Camrelizumab Plus Docetaxel and Cisplatin as First-line Therapy in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients(CHANCE): an Open-label, Single-arm, Phase II Trial
Latest Information Update: 11 Nov 2022
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary) ; Carboplatin
- Indications Carcinoma; Mouth neoplasm; Squamous cell cancer
- Focus Adverse reactions
- Acronyms CHANCE
Most Recent Events
- 11 Nov 2022 New trial record